Ebola vaccine has been 100% effective

Researchers have successfully developed the Ebola virus vaccine with efficacy of up to 100%. The results were tested on a large scale with the subjects of patients in West Africa, where Ebola raged throughout.

Although it was not timely to prevent a pandemic outbreak in 2014, the success of this vaccine was a hinge for the fight against Ebola. More than 300,000 doses are ready to deal with emergencies.

Ebola attacks Africa for a long time.

The scientific name is rVSV-EBOV and has the ability to immunize Ebola virus for all subjects. This new vaccine has undergone wide-ranging trials and is now waiting for a license from a competent authority to be used more widely.

"We will be much more proactive if there is another outbreak," said lead researcher WHO World Health Organization Marie-Paule Kieny.

Cases of Ebola infection still occur in Guinea, where the team conducted a "round-the-clock" research method to test this new vaccine. This method means that the group will be vaccinating all people who have been exposed to Ebola patients. Of the 5,837 people who were vaccinated, no new cases were detected, while in the opposite direction, up to 23 new infections out of more than thousands of subjects were not vaccinated.

Guinea is the most affected country.

The results are beyond the team's expectations, but rVSV-EBOV only works on Zaire ebolavirus , the ebola virus branch affects humans the most, while the other 4 branches do not deliver high efficiency.

This new vaccine can cause side effects, including joint pain and headaches. However, in the case of widespread outbreaks, these side effects are negligible.

The vaccine is made from vesicular stomatitis virus (a virus that causes disease in cattle but does not spread on humans) and a surface protein of the Ebola virus to stimulate the body's immune system to produce appropriate antibiotics .

Breakthrough in this vaccine study will be applied to many other diseases.

Based on the success of this new vaccine, more in-depth studies of vaccine efficacy on infants and vaccines for serious diseases such as HIV have been conducted. The team hopes that this Ebola vaccine will be licensed for circulation in 2017 here.

"Ebola has severely devastated our country but is also very proud to have contributed in part to the development of a vaccine that could prevent this transnational epidemic in the future" - Safety Minister Guinea's national health, KeIta Sakabo said.